4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Amarin Corporation plc (AMRN) operates in the Drug Manufacturers - General industry and is headquartered in Dublin, Ireland with about 80 employees. Its market capitalization is roughly $288 million. In the fiscal year ended 2025-12-31, AMRN reported $214M in revenue and ($39M) in net income.
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Interactive charts & full statements → Open the AMRN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $214M | $229M | $307M | $369M |
| Gross Profit | $121M | $81M | $166M | $242M |
| Operating Income (EBIT) | ($14M) | ($92M) | ($57M) | ($92M) |
| Net Income | ($39M) | ($82M) | ($59M) | ($106M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| Total Revenue | $42M | $45M | $49M | $50M | $73M |
| Gross Profit | $15M | $18M | $23M | $22M | $50M |
| Operating Income (EBIT) | ($12M) | ($8M) | ($2M) | ($2M) | $7M |
| Net Income | ($8M) | ($10M) | ($1M) | ($8M) | ($14M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $671M | $685M | $832M | $886M | — |
| Total Liabilities | $212M | $199M | $280M | $291M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AMRN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms